506 related articles for article (PubMed ID: 33320840)
1. Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer.
Edwards DN; Ngwa VM; Raybuck AL; Wang S; Hwang Y; Kim LC; Cho SH; Paik Y; Wang Q; Zhang S; Manning HC; Rathmell JC; Cook RS; Boothby MR; Chen J
J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33320840
[TBL] [Abstract][Full Text] [Related]
2. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
3. Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition.
Lampa M; Arlt H; He T; Ospina B; Reeves J; Zhang B; Murtie J; Deng G; Barberis C; Hoffmann D; Cheng H; Pollard J; Winter C; Richon V; Garcia-Escheverria C; Adrian F; Wiederschain D; Srinivasan L
PLoS One; 2017; 12(9):e0185092. PubMed ID: 28950000
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.
Qin Y; Vasilatos SN; Chen L; Wu H; Cao Z; Fu Y; Huang M; Vlad AM; Lu B; Oesterreich S; Davidson NE; Huang Y
Oncogene; 2019 Jan; 38(3):390-405. PubMed ID: 30111819
[TBL] [Abstract][Full Text] [Related]
5. T-bet
Mori H; Kubo M; Kai M; Yamada M; Kurata K; Kawaji H; Kaneshiro K; Osako T; Nishimura R; Arima N; Okido M; Kishimoto J; Oda Y; Nakamura M
Breast Cancer Res Treat; 2019 Aug; 176(3):569-577. PubMed ID: 31069590
[TBL] [Abstract][Full Text] [Related]
6. Tumoral PD-1hiCD8+ T cells are partially exhausted and predict favorable outcome in triple-negative breast cancer.
Guo L; Cao C; Goswami S; Huang X; Ma L; Guo Y; Yang B; Li T; Chi Y; Zhang X; Wu J
Clin Sci (Lond); 2020 Apr; 134(7):711-726. PubMed ID: 32202617
[TBL] [Abstract][Full Text] [Related]
7. [
Zhou R; Pantel AR; Li S; Lieberman BP; Ploessl K; Choi H; Blankemeyer E; Lee H; Kung HF; Mach RH; Mankoff DA
Cancer Res; 2017 Mar; 77(6):1476-1484. PubMed ID: 28202527
[TBL] [Abstract][Full Text] [Related]
8. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
[TBL] [Abstract][Full Text] [Related]
9. The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer.
Wang K; Shen T; Siegal GP; Wei S
Hum Pathol; 2017 Nov; 69():110-117. PubMed ID: 28993275
[TBL] [Abstract][Full Text] [Related]
10. Role of inflammatory infiltrates in triple negative breast cancer.
Matsumoto H; Koo SL; Dent R; Tan PH; Iqbal J
J Clin Pathol; 2015 Jul; 68(7):506-10. PubMed ID: 25750267
[TBL] [Abstract][Full Text] [Related]
11. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer.
van Geldermalsen M; Wang Q; Nagarajah R; Marshall AD; Thoeng A; Gao D; Ritchie W; Feng Y; Bailey CG; Deng N; Harvey K; Beith JM; Selinger CI; O'Toole SA; Rasko JE; Holst J
Oncogene; 2016 Jun; 35(24):3201-8. PubMed ID: 26455325
[TBL] [Abstract][Full Text] [Related]
12. PARP Inhibitor Efficacy Depends on CD8
Pantelidou C; Sonzogni O; De Oliveria Taveira M; Mehta AK; Kothari A; Wang D; Visal T; Li MK; Pinto J; Castrillon JA; Cheney EM; Bouwman P; Jonkers J; Rottenberg S; Guerriero JL; Wulf GM; Shapiro GI
Cancer Discov; 2019 Jun; 9(6):722-737. PubMed ID: 31015319
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral Plasmid IL12 Expands CD8
Telli ML; Nagata H; Wapnir I; Acharya CR; Zablotsky K; Fox BA; Bifulco CB; Jensen SM; Ballesteros-Merino C; Le MH; Pierce RH; Browning E; Hermiz R; Svenson L; Bannavong D; Jaffe K; Sell J; Foerter KM; Canton DA; Twitty CG; Osada T; Lyerly HK; Crosby EJ
Clin Cancer Res; 2021 May; 27(9):2481-2493. PubMed ID: 33593880
[TBL] [Abstract][Full Text] [Related]
14. Tumor-infiltrating exhausted CD8+ T cells dictate reduced survival in premenopausal estrogen receptor-positive breast cancer.
Egelston CA; Guo W; Tan J; Avalos C; Simons DL; Lim MH; Huang YJ; Nelson MS; Chowdhury A; Schmolze DB; Yim JH; Kruper L; Melstrom L; Margolin K; Mortimer JE; Yuan Y; Waisman JR; Lee PP
JCI Insight; 2022 Feb; 7(3):. PubMed ID: 35132960
[TBL] [Abstract][Full Text] [Related]
15. Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer.
Singleton DC; Dechaume AL; Murray PM; Katt WP; Baguley BC; Leung EY
BMC Cancer; 2020 May; 20(1):470. PubMed ID: 32450839
[TBL] [Abstract][Full Text] [Related]
16. Sphingomyelin synthase 2 facilitates M2-like macrophage polarization and tumor progression in a mouse model of triple-negative breast cancer.
Deng Y; Hu JC; He SH; Lou B; Ding TB; Yang JT; Mo MG; Ye DY; Zhou L; Jiang XC; Yu K; Dong JB
Acta Pharmacol Sin; 2021 Jan; 42(1):149-159. PubMed ID: 32451413
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer.
Gross MI; Demo SD; Dennison JB; Chen L; Chernov-Rogan T; Goyal B; Janes JR; Laidig GJ; Lewis ER; Li J; Mackinnon AL; Parlati F; Rodriguez ML; Shwonek PJ; Sjogren EB; Stanton TF; Wang T; Yang J; Zhao F; Bennett MK
Mol Cancer Ther; 2014 Apr; 13(4):890-901. PubMed ID: 24523301
[TBL] [Abstract][Full Text] [Related]
18. An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers.
Bottai G; Raschioni C; Losurdo A; Di Tommaso L; Tinterri C; Torrisi R; Reis-Filho JS; Roncalli M; Sotiriou C; Santoro A; Mantovani A; Loi S; Santarpia L
Breast Cancer Res; 2016 Dec; 18(1):121. PubMed ID: 27912781
[TBL] [Abstract][Full Text] [Related]
19. LXR-inverse agonism stimulates immune-mediated tumor destruction by enhancing CD8 T-cell activity in triple negative breast cancer.
Carpenter KJ; Valfort AC; Steinauer N; Chatterjee A; Abuirqeba S; Majidi S; Sengupta M; Di Paolo RJ; Shornick LP; Zhang J; Flaveny CA
Sci Rep; 2019 Dec; 9(1):19530. PubMed ID: 31863071
[TBL] [Abstract][Full Text] [Related]
20. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
